- Home
- WAFU vs MYNZ Comparison
WAFU vs MYNZ Comparison
Compare WAFU & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WAFU | MYNZ |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | China | Germany |
| Employees | N/A | 26 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WAFU | MYNZ |
|---|---|---|
| Price | $1.67 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 11.4K | ★ 305.7K |
| Earning Date | 01-01-0001 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,186,645.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.92 |
| 52 Week High | $7.49 | $8.20 |
Technical Indicators
Market Signals| Indicator | WAFU | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 35.34 |
| Support Level | $1.60 | $1.00 |
| Resistance Level | $1.68 | $1.15 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 25.00 | 5.26 |
Price Performance
Historical ComparisonAbout WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.